Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Last two presentations

<< Previous

Bullboard Posts

Next >>

Comment by Mannequinon Aug 23, 2023 5:43pm

74 Views

Post# 35602759

RE:Last two presentations

Surely they should have know the costs before they did the deal. But don't call me surely.

scarlet1967 wrote:

Stockhouse doesn't let me paste the presentations! But it seems like about 15 employees have been laid off so far! As per previous announcements mostly R&D personal! The adjusted EBIDTA Q1, 2023 was minus $3.9M compared to first half of the 2023, minus $10M including the $4.4M of expenses related to oncology project. I really believe a bit more transparency regarding the financials and their plan of action going forward in order to meet the minimum liquidity requirement set by Marathon, approximate remaining costs for the restart, achieving positive EBIDTA etc. is really a must to do so all these talks about oncology costing 10s of millions or the company going bankrupt without any real numbers disclosed can end. Surely they should have factored in the cost savings and added costs due to oncology program among others before predicting the generation of adjusted positive EBIDTA by end of this calendar year.